Symbols / AXSM
AXSM Chart
About
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.57B |
| Enterprise Value | 8.54B | Income | -183.17M | Sales | 638.50M |
| Book/sh | 1.74 | Cash/sh | 6.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 28.48 | PEG | — |
| P/S | 13.42 | P/B | 97.95 | P/C | — |
| EV/EBITDA | -52.60 | EV/Sales | 13.38 | Quick Ratio | 1.45 |
| Current Ratio | 1.55 | Debt/Eq | 244.15 | LT Debt/Eq | — |
| EPS (ttm) | -4.67 | EPS next Y | 5.97 | EPS Growth | — |
| Revenue Growth | 65.00% | Earnings | 2026-05-04 | ROA | -16.81% |
| ROE | -252.12% | ROIC | — | Gross Margin | 92.56% |
| Oper. Margin | -18.38% | Profit Margin | -28.69% | Shs Outstand | 50.41M |
| Shs Float | 42.89M | Short Float | 6.40% | Short Ratio | 3.16 |
| Short Interest | — | 52W High | 191.50 | 52W Low | 86.99 |
| Beta | 0.40 | Avg Volume | 629.36K | Volume | 1.06M |
| Target Price | $222.47 | Recom | Strong_buy | Prev Close | $174.76 |
| Price | $169.95 | Change | -2.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$222.47
Mean price target
2. Current target
$169.95
Latest analyst target
3. DCF / Fair value
$222.47
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$169.95
Low
$198.82
High
$260.00
Mean
$222.47
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | UBS | Buy → Buy | $251 |
| 2026-02-24 | main | Guggenheim | Buy → Buy | $220 |
| 2026-02-24 | main | RBC Capital | Outperform → Outperform | $222 |
| 2026-02-24 | main | Wells Fargo | Overweight → Overweight | $202 |
| 2026-02-24 | init | Wolfe Research | — → Outperform | $230 |
| 2026-02-23 | reit | Needham | Buy → Buy | $225 |
| 2026-02-03 | main | Jefferies | Buy → Buy | $245 |
| 2026-01-28 | main | Leerink Partners | Outperform → Outperform | $205 |
| 2026-01-21 | main | RBC Capital | Outperform → Outperform | $219 |
| 2026-01-20 | main | HC Wainwright & Co. | Buy → Buy | $260 |
| 2026-01-16 | main | Piper Sandler | Overweight → Overweight | $223 |
| 2026-01-13 | main | Wells Fargo | Overweight → Overweight | $193 |
| 2026-01-08 | down | Morgan Stanley | Overweight → Equal-Weight | $204 |
| 2026-01-06 | main | UBS | Buy → Buy | $248 |
| 2026-01-05 | main | HC Wainwright & Co. | Buy → Buy | $200 |
| 2025-12-31 | main | Needham | Buy → Buy | $169 |
| 2025-11-06 | main | Mizuho | Outperform → Outperform | $202 |
| 2025-11-04 | main | Morgan Stanley | Overweight → Overweight | $196 |
| 2025-11-04 | main | HC Wainwright & Co. | Buy → Buy | $185 |
| 2025-11-04 | main | RBC Capital | Outperform → Outperform | $198 |
- AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - Nasdaq ue, 24 Feb 2026 17
- Axsome Therapeutics (AXSM) Receives Updated Analyst Rating and T - GuruFocus ue, 24 Feb 2026 15
- Why The Axsome Therapeutics (AXSM) Story Is Shifting As Analysts Rework Valuation Models - Yahoo Finance Mon, 23 Feb 2026 16
- Assessing Axsome Therapeutics (AXSM) Valuation After SUNOSI Patent Settlement With Alkem - simplywall.st Mon, 23 Feb 2026 13
- HighTower Advisors LLC Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat Mon, 23 Feb 2026 10
- Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued (AXSM) - Seeking Alpha Mon, 23 Feb 2026 17
- Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits Mon, 23 Feb 2026 20
- Liquidity Mapping Around (AXSM) Price Events - Stock Traders Daily Mon, 23 Feb 2026 09
- Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance Mon, 23 Feb 2026 15
- Axsome Therapeutics, Inc. $AXSM Stock Holdings Lifted by Aberdeen Group plc - MarketBeat Fri, 20 Feb 2026 09
- Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings - Nasdaq Mon, 23 Feb 2026 16
- Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Down - Should You Sell? - MarketBeat Mon, 23 Feb 2026 19
- Axsome Therapeutics Q4 Revenue Surge Tests Bulls’ Profitability Narrative - simplywall.st ue, 24 Feb 2026 14
- Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates - Yahoo Finance ue, 03 Feb 2026 08
- Axsome Therapeutics, Inc. $AXSM Shares Sold by Granite Investment Partners LLC - MarketBeat Mon, 23 Feb 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5193 | 41648 | — | Conversion of Exercise of derivative security at price 8.02 per share. | COLEMAN MARK H | Director | — | 2026-02-10 00:00:00 | D |
| 1 | 32410 | 6015296 | — | Sale at price 185.60 per share. | TABUTEAU HERRIOT | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 32410 | 259928 | — | Conversion of Exercise of derivative security at price 8.02 per share. | TABUTEAU HERRIOT | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 12000 | 2255040 | — | Sale at price 187.92 per share. | PIZZIE NICK | Chief Financial Officer | — | 2026-01-22 00:00:00 | D |
| 4 | 12000 | 42000 | — | Conversion of Exercise of derivative security at price 3.50 per share. | PIZZIE NICK | Chief Financial Officer | — | 2026-01-22 00:00:00 | D |
| 5 | 7500 | 1383300 | — | Sale at price 184.44 per share. | MAIZEL ARI | Officer | — | 2026-01-21 00:00:00 | D |
| 6 | 7500 | 530475 | — | Conversion of Exercise of derivative security at price 70.73 per share. | MAIZEL ARI | Officer | — | 2026-01-21 00:00:00 | D |
| 7 | 139414 | 23881618 | — | Sale at price 170.38 - 172.33 per share. | TABUTEAU HERRIOT | Chief Executive Officer | — | 2026-01-07 00:00:00 | D |
| 8 | 139414 | 1118100 | — | Conversion of Exercise of derivative security at price 8.02 per share. | TABUTEAU HERRIOT | Chief Executive Officer | — | 2026-01-07 00:00:00 | D |
| 9 | 37577 | 6206969 | — | Sale at price 165.18 per share. | SAAD MARK E | Director | — | 2025-12-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -10.27M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -244.48M | -176.07M | -172.10M | -124.63M |
| TotalUnusualItems | -28.12M | -48.92M | -3.30M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -28.12M | -48.92M | -3.30M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -287.22M | -239.24M | -187.13M | -130.40M |
| ReconciledDepreciation | 7.96M | 6.83M | 4.40M | 76.00K |
| ReconciledCostOfRevenue | 31.74M | 25.61M | 4.93M | 0.00 |
| EBITDA | -272.60M | -224.99M | -175.40M | -124.63M |
| EBIT | -280.56M | -231.82M | -179.80M | -124.71M |
| NetInterestIncome | -6.57M | -6.45M | -7.33M | -5.70M |
| InterestExpense | 6.57M | 6.45M | 7.33M | 5.70M |
| NormalizedIncome | -259.09M | -200.59M | -183.84M | -130.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -287.22M | -239.24M | -187.13M | -130.40M |
| TotalExpenses | 638.13M | 453.51M | 226.54M | 124.71M |
| TotalOperatingIncomeAsReported | -280.56M | -231.82M | -179.80M | -124.71M |
| DilutedAverageShares | 47.91M | 45.43M | 40.66M | 37.62M |
| BasicAverageShares | 47.91M | 45.43M | 40.66M | 37.62M |
| DilutedEPS | -5.99 | -5.27 | -4.60 | -3.47 |
| BasicEPS | -5.99 | -5.27 | -4.60 | -3.47 |
| DilutedNIAvailtoComStockholders | -287.22M | -239.24M | -187.13M | -130.40M |
| NetIncomeCommonStockholders | -287.22M | -239.24M | -187.13M | -130.40M |
| NetIncome | -287.22M | -239.24M | -187.13M | -130.40M |
| NetIncomeIncludingNoncontrollingInterests | -287.22M | -239.24M | -187.13M | -130.40M |
| NetIncomeContinuousOperations | -287.22M | -239.24M | -187.13M | -130.40M |
| TaxProvision | 85.00K | 960.00K | 0.00 | 0.00 |
| PretaxIncome | -287.13M | -238.28M | -187.13M | -130.40M |
| OtherIncomeExpense | -28.12M | -48.92M | -3.30M | |
| SpecialIncomeCharges | -28.12M | -48.92M | -3.30M | 0.00 |
| RestructuringAndMergernAcquisition | 28.12M | 48.92M | 3.30M | 0.00 |
| NetNonOperatingInterestIncomeExpense | -6.57M | -6.45M | -7.33M | -5.70M |
| InterestExpenseNonOperating | 6.57M | 6.45M | 7.33M | 5.70M |
| OperatingIncome | -252.44M | -182.91M | -176.50M | -124.71M |
| OperatingExpense | 604.83M | 427.44M | 221.34M | 124.71M |
| OtherTaxes | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletionIncomeStatement | 6.39M | 6.38M | 4.14M | 0.00 |
| DepreciationAndAmortizationInIncomeStatement | 6.39M | 6.38M | 4.14M | 0.00 |
| Amortization | 6.39M | 6.38M | 4.14M | 0.00 |
| AmortizationOfIntangiblesIncomeStatement | 6.39M | 6.38M | 4.14M | 0.00 |
| ResearchAndDevelopment | 187.08M | 97.94M | 57.95M | 58.06M |
| SellingGeneralAndAdministration | 411.36M | 323.12M | 159.25M | 66.65M |
| GeneralAndAdministrativeExpense | 66.65M | |||
| OtherGandA | 66.65M | |||
| GrossProfit | 352.39M | 244.53M | 44.84M | 0.00 |
| CostOfRevenue | 33.30M | 26.07M | 5.20M | 0.00 |
| TotalRevenue | 385.69M | 270.60M | 50.04M | 0.00 |
| OperatingRevenue | 385.69M | 270.60M | 50.04M | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 48.67M | 47.35M | 43.50M | 37.82M |
| ShareIssued | 48.67M | 47.35M | 43.50M | 37.82M |
| TotalDebt | 192.96M | 186.37M | 94.68M | 49.71M |
| TangibleBookValue | -1.92M | 125.65M | 39.59M | 15.63M |
| InvestedCapital | 237.72M | 369.05M | 203.81M | 64.72M |
| WorkingCapital | 254.96M | 365.41M | 149.08M | 63.45M |
| NetTangibleAssets | -1.92M | 125.65M | 39.59M | 15.63M |
| CapitalLeaseObligations | 12.24M | 8.30M | 425.00K | 620.67K |
| CommonStockEquity | 57.02M | 190.98M | 109.56M | 15.63M |
| TotalCapitalization | 237.72M | 369.05M | 203.81M | 64.72M |
| TotalEquityGrossMinorityInterest | 57.02M | 190.98M | 109.56M | 15.63M |
| StockholdersEquity | 57.02M | 190.98M | 109.56M | 15.63M |
| RetainedEarnings | -1.12B | -835.57M | -596.33M | -409.20M |
| AdditionalPaidInCapital | 1.18B | 1.03B | 705.88M | 424.83M |
| CapitalStock | 5.00K | 5.00K | 4.00K | 3.78K |
| CommonStock | 5.00K | 5.00K | 4.00K | 3.78K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 511.48M | 397.26M | 221.92M | 72.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 281.38M | 258.40M | 125.36M | 49.09M |
| OtherNonCurrentLiabilities | 91.68M | 73.30M | 31.10M | |
| LongTermDebtAndCapitalLeaseObligation | 189.70M | 185.10M | 94.26M | 49.09M |
| LongTermCapitalLeaseObligation | 8.99M | 7.04M | 0.00 | 0.00 |
| LongTermDebt | 180.71M | 178.07M | 94.26M | 49.09M |
| CurrentLiabilities | 230.10M | 138.85M | 96.56M | 23.07M |
| OtherCurrentLiabilities | 8.29M | 6.41M | 5.90M | |
| CurrentDebtAndCapitalLeaseObligation | 3.26M | 1.27M | 425.00K | 620.67K |
| CurrentCapitalLeaseObligation | 3.26M | 1.27M | 425.00K | 620.67K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 28.23M | 20.46M | 11.28M | 4.05M |
| PayablesAndAccruedExpenses | 190.34M | 110.72M | 78.95M | 18.39M |
| CurrentAccruedExpenses | 117.38M | 70.04M | 40.35M | 5.24M |
| InterestPayable | 1.54M | 1.66M | 875.00K | 385.35K |
| Payables | 72.96M | 40.68M | 38.60M | 13.15M |
| TotalTaxPayable | 960.00K | 0.00 | ||
| AccountsPayable | 72.00M | 40.68M | 38.60M | 13.15M |
| TotalAssets | 568.50M | 588.24M | 331.48M | 87.79M |
| TotalNonCurrentAssets | 83.43M | 83.97M | 85.83M | 1.27M |
| OtherNonCurrentAssets | 18.53M | 11.03M | 14.72M | 322.91K |
| GoodwillAndOtherIntangibleAssets | 58.94M | 65.33M | 69.97M | 0.00 |
| OtherIntangibleAssets | 46.89M | 53.29M | 59.66M | |
| Goodwill | 12.04M | 12.04M | 10.31M | 0.00 |
| NetPPE | 5.97M | 7.62M | 1.14M | 944.01K |
| GrossPPE | 5.97M | 7.62M | 1.14M | 944.01K |
| OtherProperties | 584.00K | 846.00K | 722.00K | 283.85K |
| BuildingsAndImprovements | 5.38M | 6.77M | 420.00K | 660.16K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 485.06M | 504.26M | 245.64M | 86.52M |
| OtherCurrentAssets | 11.98M | 8.12M | 2.78M | 45.29K |
| PrepaidAssets | 45.29K | |||
| Inventory | 15.73M | 15.13M | 4.32M | 0.00 |
| Receivables | 142.00M | 94.82M | 37.70M | 0.00 |
| AccountsReceivable | 142.00M | 94.82M | 37.70M | 0.00 |
| AllowanceForDoubtfulAccountsReceivable | -13.50M | -12.50M | -9.10M | |
| GrossAccountsReceivable | 155.50M | 107.32M | 46.80M | |
| CashCashEquivalentsAndShortTermInvestments | 315.35M | 386.19M | 200.84M | 86.47M |
| CashAndCashEquivalents | 315.35M | 386.19M | 200.84M | 86.47M |
| CashFinancial | 86.47M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -128.68M | -145.66M | -117.21M | -108.53M |
| RepaymentOfDebt | -990.00K | 0.00 | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 85.00M | 45.00M | 0.00 |
| IssuanceOfCapitalStock | 40.78M | 258.75M | 243.76M | 7.44M |
| CapitalExpenditure | -270.00K | -582.00K | -702.00K | -308.00K |
| InterestPaidSupplementalData | 19.69M | 16.73M | 7.69M | 4.62M |
| EndCashPosition | 315.35M | 386.19M | 200.84M | 86.47M |
| BeginningCashPosition | 386.19M | 200.84M | 86.47M | 183.88M |
| ChangesInCash | -70.84M | 185.35M | 114.37M | -97.40M |
| FinancingCashFlow | 57.84M | 331.01M | 284.58M | 11.13M |
| CashFlowFromContinuingFinancingActivities | 57.84M | 331.01M | 284.58M | 11.13M |
| NetOtherFinancingCharges | -12.63M | -25.16M | -10.43M | -708.00K |
| ProceedsFromStockOptionExercised | 30.68M | 12.42M | 6.25M | 4.40M |
| NetCommonStockIssuance | 40.78M | 258.75M | 243.76M | 7.44M |
| CommonStockIssuance | 40.78M | 258.75M | 243.76M | 7.44M |
| NetIssuancePaymentsOfDebt | -990.00K | 85.00M | 45.00M | 0.00 |
| NetLongTermDebtIssuance | -990.00K | 85.00M | 45.00M | 0.00 |
| LongTermDebtPayments | -990.00K | 0.00 | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 85.00M | 45.00M | 0.00 |
| InvestingCashFlow | -270.00K | -582.00K | -53.70M | -308.00K |
| CashFlowFromContinuingInvestingActivities | -270.00K | -582.00K | -53.70M | -308.00K |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -53.00M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -53.00M | 0.00 |
| NetPPEPurchaseAndSale | -270.00K | -582.00K | -702.00K | -308.00K |
| PurchaseOfPPE | -270.00K | -582.00K | -702.00K | -308.00K |
| OperatingCashFlow | -128.41M | -145.08M | -116.51M | -108.23M |
| CashFlowFromContinuingOperatingActivities | -128.41M | -145.08M | -116.51M | -108.23M |
| ChangeInWorkingCapital | 33.90M | -28.39M | 23.67M | 324.00K |
| ChangeInOtherCurrentAssets | -5.54K | |||
| ChangeInPayablesAndAccruedExpense | 87.38M | 38.53M | 69.38M | 227.00K |
| ChangeInAccruedExpense | 56.06M | 36.45M | 43.92M | 582.00K |
| ChangeInPayable | 31.32M | 2.07M | 25.46M | -355.00K |
| ChangeInAccountPayable | 31.32M | 2.07M | 25.46M | -355.00K |
| ChangeInPrepaidAssets | -3.86M | -5.33M | -2.73M | 103.00K |
| ChangeInInventory | -2.44M | -4.46M | -5.28M | -6.00K |
| ChangeInReceivables | -47.18M | -57.12M | -37.70M | 0.00 |
| ChangesInAccountReceivables | -47.18M | -57.12M | -37.70M | 0.00 |
| OtherNonCashItems | 31.73M | 53.10M | 4.83M | 974.00K |
| StockBasedCompensation | 85.22M | 62.62M | 37.73M | 20.80M |
| DepreciationAmortizationDepletion | 7.96M | 6.83M | 4.40M | 76.00K |
| DepreciationAndAmortization | 7.96M | 6.83M | 4.40M | 76.00K |
| AmortizationCashFlow | 6.39M | 6.38M | 4.14M | 0.00 |
| AmortizationOfIntangibles | 6.39M | 6.38M | 4.14M | 0.00 |
| Depreciation | 1.57M | 459.00K | 263.00K | 76.00K |
| NetIncomeFromContinuingOperations | -287.22M | -239.24M | -187.13M | -130.40M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AXSM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|